Leo Lens solves the glaucoma treatment problem with a non-invasive automatic dosing weekly therapy which helps limit the progression of the disease and helps protect sight. With its MediPrint technology and proven execution team in place, Leo Lens can create significant value from a $2M Seed round advancing to Phase 3 clinical trials.